Merge solidifies sales team for Chinese market

TriMed Staff | | Health Imaging | Artificial Intelligence
Merge Healthcare has solidified sales operations for ShanghaiCo, and is now doing business as Merge China.

Justin Dearborn, Merge CEO, said that “China has the potential to be our biggest market in a few years.”

Merge China was reacquired after the dissolution of a transfer agreement to Inqgen Technology earlier this month.

Zhong Wang, who leads Merge China, has built a team that includes: Diana Dai, sales manager, and Weiming Li, customer operations manager, will lead business development efforts with Wang; Feng Chen will lead engineering; XinLiang Li will lead customer service, and Wei Chen will lead HR, finance and administration, according to the Milwaukee, Wis.-base company.

TriMed Staff

Related Content

Could synthetic images replace the need for contrast?
Experts developing AI model that learns from calcium-scoring CT scans
FDA has approved over 1,000 clinical AI applications, with most aimed at radiology
Commercially available AI increases breast cancer detection by nearly 20%
Clinicians want AI to show its work
ACR Assess-AI national data registry tracks performance of clinical algorithms

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.